The NEWFLAME trial, investigating nivolumab plus abemaciclib plus ET (fulvestrant or letrozole) as a first- or second-line treatment for patients with HR+, HER2−, MBC, reported similar safety findings to this study, including high rates of treatment discontinuation, elevated liver function tests, and ILD/pneumonitis25. This evidence concerns the gene ERBB2 and interstitial lung disease.